Strengthening Pharmacovigilance for Cardiovascular and Diuretic Agents: Challenges, Trends, and Future Directions
Session
Pharmaceutical and Natural Sciences
Description
Cardiovascular and diuretic agents are among the most widely prescribed drug classes globally, particularly in aging populations with comorbidities such as hypertension, heart failure, and chronic kidney disease. Despite their therapeutic benefits, these agents are frequently associated with adverse drug reactions (ADRs), including electrolyte imbalances, renal dysfunction, hypotension, and arrhythmias. The aim of this work is to explore the current landscape of pharmacovigilance related to cardiovascular and diuretic drugs, highlighting trends in ADR reporting, underreporting challenges, and signal detection methods. Real-world case data and post-marketing surveillance findings will be discussed to underscore the importance of early risk identification and mitigation. Additionally, we will propose strategies to enhance pharmacovigilance systems—such as leveraging digital health tools and promoting stakeholder education—to ensure drug safety and optimize patient outcomes.
Keywords:
Drugs, cardiovascular agents, diuretics, pharmacovigilance, ADRs
Proceedings Editor
Edmond Hajrizi
ISBN
978-9951-982-41-2
Location
UBT Lipjan, Kosovo
Start Date
25-10-2025 9:00 AM
End Date
26-10-2025 6:00 PM
DOI
10.33107/ubt-ic.2025.347
Recommended Citation
Ejupi, Valon; Qazimi, Bujar; Dragusha, Shpend; Bajraktari, Demush; Tahiri, Diellza; Krasniqi, Dafina; and Hoti, Agon, "Strengthening Pharmacovigilance for Cardiovascular and Diuretic Agents: Challenges, Trends, and Future Directions" (2025). UBT International Conference. 9.
https://knowledgecenter.ubt-uni.net/conference/2025UBTIC/PNS/9
Strengthening Pharmacovigilance for Cardiovascular and Diuretic Agents: Challenges, Trends, and Future Directions
UBT Lipjan, Kosovo
Cardiovascular and diuretic agents are among the most widely prescribed drug classes globally, particularly in aging populations with comorbidities such as hypertension, heart failure, and chronic kidney disease. Despite their therapeutic benefits, these agents are frequently associated with adverse drug reactions (ADRs), including electrolyte imbalances, renal dysfunction, hypotension, and arrhythmias. The aim of this work is to explore the current landscape of pharmacovigilance related to cardiovascular and diuretic drugs, highlighting trends in ADR reporting, underreporting challenges, and signal detection methods. Real-world case data and post-marketing surveillance findings will be discussed to underscore the importance of early risk identification and mitigation. Additionally, we will propose strategies to enhance pharmacovigilance systems—such as leveraging digital health tools and promoting stakeholder education—to ensure drug safety and optimize patient outcomes.